Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors

Lee E. Moore; Michael L. Nickerson; Paul Brennan; Jorge R. Toro; Erich Jaeger; Jessica Rinsky; Summer S. Han; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Laura S. Schmidt; Petra Lenz; Sara Karami; W. Marston Linehan; Maria Merino; Stephen Chanock; Paolo Boffetta; Wong Ho Chow; Frederic M. Waldman; Nathaniel Rothman

doi:10.1371/journal.pgen.1002312

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors

Lee E. Moore, Michael L. Nickerson, Paul Brennan, Jorge R. Toro, Erich Jaeger, Jessica Rinsky, Summer S. Han, David Zaridze, Vsevolod Matveev, Vladimir Janout, Hellena Kollarova, Vladimir Bencko, Marie Navratilova, Neonilia Szeszenia-Dabrowska, Dana Mates, Laura S. Schmidt, Petra Lenz, Sara Karami, W. Marston Linehan, Maria MerinoStephen Chanock, Paolo Boffetta, Wong Ho Chow, Frederic M. Waldman, Nathaniel Rothman

Research output: Contribution to journal › Article › peer-review

135 Scopus citations

Abstract

Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.

Original language	English (US)
Article number	e1002312
Journal	PLoS genetics
Volume	7
Issue number	10
DOIs	https://doi.org/10.1371/journal.pgen.1002312
State	Published - Oct 2011
Externally published	Yes

ASJC Scopus subject areas

Ecology, Evolution, Behavior and Systematics
Molecular Biology
Genetics
Genetics(clinical)
Cancer Research

Access to Document

10.1371/journal.pgen.1002312

Cite this

Moore, L. E., Nickerson, M. L., Brennan, P., Toro, J. R., Jaeger, E., Rinsky, J., Han, S. S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., Navratilova, M., Szeszenia-Dabrowska, N., Mates, D., Schmidt, L. S., Lenz, P., Karami, S., Linehan, W. M., ... Rothman, N. (2011). Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors. PLoS genetics, 7(10), Article e1002312. https://doi.org/10.1371/journal.pgen.1002312

Moore, LE, Nickerson, ML, Brennan, P, Toro, JR, Jaeger, E, Rinsky, J, Han, SS, Zaridze, D, Matveev, V, Janout, V, Kollarova, H, Bencko, V, Navratilova, M, Szeszenia-Dabrowska, N, Mates, D, Schmidt, LS, Lenz, P, Karami, S, Linehan, WM, Merino, M, Chanock, S, Boffetta, P, Chow, WH, Waldman, FM & Rothman, N 2011, 'Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors', PLoS genetics, vol. 7, no. 10, e1002312. https://doi.org/10.1371/journal.pgen.1002312

@article{a63814ac9be44e1a80c2a60a936d97b5,

title = "Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors",

abstract = "Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.",

author = "Moore, {Lee E.} and Nickerson, {Michael L.} and Paul Brennan and Toro, {Jorge R.} and Erich Jaeger and Jessica Rinsky and Han, {Summer S.} and David Zaridze and Vsevolod Matveev and Vladimir Janout and Hellena Kollarova and Vladimir Bencko and Marie Navratilova and Neonilia Szeszenia-Dabrowska and Dana Mates and Schmidt, {Laura S.} and Petra Lenz and Sara Karami and Linehan, {W. Marston} and Maria Merino and Stephen Chanock and Paolo Boffetta and Chow, {Wong Ho} and Waldman, {Frederic M.} and Nathaniel Rothman",

year = "2011",

month = oct,

doi = "10.1371/journal.pgen.1002312",

language = "English (US)",

volume = "7",

journal = "PLoS genetics",

issn = "1553-7390",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer

T2 - Associations with germline VHL polymorphisms and etiologic risk factors

AU - Moore, Lee E.

AU - Nickerson, Michael L.

AU - Brennan, Paul

AU - Toro, Jorge R.

AU - Jaeger, Erich

AU - Rinsky, Jessica

AU - Han, Summer S.

AU - Zaridze, David

AU - Matveev, Vsevolod

AU - Janout, Vladimir

AU - Kollarova, Hellena

AU - Bencko, Vladimir

AU - Navratilova, Marie

AU - Szeszenia-Dabrowska, Neonilia

AU - Mates, Dana

AU - Schmidt, Laura S.

AU - Lenz, Petra

AU - Karami, Sara

AU - Linehan, W. Marston

AU - Merino, Maria

AU - Chanock, Stephen

AU - Boffetta, Paolo

AU - Chow, Wong Ho

AU - Waldman, Frederic M.

AU - Rothman, Nathaniel

PY - 2011/10

Y1 - 2011/10

N2 - Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.

AB - Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR = 6.10; 95% CI: 2.28-16.35, p = 3.76E-4, p-global = 8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher proportion of wild-type ccRCC tumors [former: OR = 0.70 (0.20-1.31) and current: OR = 0.56 (0.32-0.99); P-trend = 0.04]. Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical entity from inactivated cases.

UR - http://www.scopus.com/inward/record.url?scp=80055069795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055069795&partnerID=8YFLogxK

U2 - 10.1371/journal.pgen.1002312

DO - 10.1371/journal.pgen.1002312

M3 - Article

C2 - 22022277

AN - SCOPUS:80055069795

SN - 1553-7390

VL - 7

JO - PLoS genetics

JF - PLoS genetics

IS - 10

M1 - e1002312

ER -

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this